Comparison of Clopidogrel and Ticagrelor for Dual Antiplatelet Therapy of Patients with Unruptured Cerebral Aneurysms Undergoing Endovascular Treatment

Kevin D. Hurtado-Ortiz, Andres F. Ortiz-Giraldo, Daniela D Vera-Camargo, Carolina Valenzuela-Santos, Sauder A. Cardenas-Sanchez, Paula A. Correa-Ruiz, Carlos A. Ferreira-Prada, Melquizidel Galvis, Oliverio Vargas-Pérez, Sergio Serrano-Gómez (Co-autor), Adriana Reyes (Co-autor), Daniel E. Mantilla-Garcia (Co-autor)

Producción científica: Artículos / NotasArtículo Científicorevisión exhaustiva

3 Citas (Scopus)

Resumen

Background: Thromboembolic events are critical complications in neuroendovascular procedures, and dual antiplatelet therapy (DAPT) can reduce them. The effects of using aspirin and clopidogrel in DAPT are well characterized, but use of aspirin and ticagrelor has been less studied. Methods: This retrospective cohort study, conducted between April 1, 2015, and December 30, 2020, included patients with endovascular treatment with flow-diverting and non–flow-diverting stents for unruptured cerebral aneurysms who received DAPT with aspirin and clopidogrel or with aspirin and ticagrelor. Results: Of 148 patients with unruptured intracranial aneurysms with flow-diverting and non–flow-diverting stents started on DAPT with aspirin (100 mg/day) and clopidogrel (75 mg/day), 24 had a poor response to clopidogrel according to the VerifyNow test and had DAPT changed to aspirin (100 mg/day) and ticagrelor (90 mg every 12 hours). One thrombotic complication (0.81%) and 1 bleeding complication (0.81%) occurred in patients receiving DAPT with clopidogrel and aspirin during the procedure. These complications did not occur (0.00%) in patients receiving DAPT with ticagrelor and aspirin. At the 6-month follow-up, 4 patients (3.15%) in the clopidogrel group presented with thrombotic complications, whereas no patients (0.00%) in the ticagrelor group experienced this complication. At 6-month follow-up, 4 patients (3.23%) in the clopidogrel group presented with hemorrhagic complications, whereas only 1 patient (4.17%) in the ticagrelor group experienced this complication. Conclusions: Our study showed that DAPT with ticagrelor (90 mg every 12 hours) and aspirin (100 mg/day) is a safe and effective alternative to DAPT with clopidogrel (75 mg/day) and aspirin (100 mg/day) for patients with an inadequate response to clopidogrel.

Idioma originalInglés
Páginas (desde-hasta)e408-e414
PublicaciónWorld Neurosurgery
Volumen177
DOI
EstadoPublicada - sep. 2023

Huella

Profundice en los temas de investigación de 'Comparison of Clopidogrel and Ticagrelor for Dual Antiplatelet Therapy of Patients with Unruptured Cerebral Aneurysms Undergoing Endovascular Treatment'. En conjunto forman una huella única.

Citar esto